[Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].
Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries.
Miakova
N V
NV
Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow.
Aleĭnikova
O V
OV
Hartmann
R
R
Rudneva
A E
AE
Trubina
N M
NM
Fechina
L G
LG
Timakov
A M
AM
Shamardina
A V
AV
Lebedev
V V
VV
Varfolomeeva
S Iu
SIu
Dudkin
S D
SD
Dyshlevaia
Z M
ZM
Timofeeva
V N
VN
Rumiantsev
A G
AG
Henze
H
H
Karachunskiĭ
A I
AI
D000293:Adolescent; D000367:Age Factors; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D002094:Republic of Belarus; D012307:Risk Factors; D012426:Russia; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D008727:Methotrexate